Please assess the completion status of the following clinical trial:

Trial Title: Study of HL-085 in NRAS Mutant Advanced Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically or cytologically confirmed unresectable Stage III or Stage IV melanoma according to AJCC (Version 7, 2010).~2. Subjects must have NRAS mutation in melanoma.~3. Chemotherapy, immunotherapy or radiotherapy ≥ 4 weeks prior to starting the study treatment. Surgery (except for tumor biopsy) or severe trauma ≤ 14 days prior to starting the study treatment.~4. ECOG performance status of 0-1.~5. Life expectancy ≥ 3 months.~6. Ability to take the medicine orally.~7. Ability to understand and the willingness to sign a written informed consent document.~Exclusion Criteria:~1. Prior therapy with a MEK-inhibitor~2. Patients with known hypersensitivity to study drug ingredients or their analogues.~3. Active central nervous system (CNS) lesion.~4. ECG QTcB≥480msec in screening, or history of congenital long QT syndrome.~5. Subjects with bleeding symptoms at Grade 3 (NCI-CTCAE v4.03) within 4 weeks prior to starting study treatment.~6. Uncontrolled concomitant diseases or infectious diseases.~7. Retinal diseases (Retinal Vein Occlusion (RVO) or Retinal pigment epithelial detachment (RPED) , et al.).~8. History of HIV,HCV,HBV infection.~9. Interstitial lung disease or interstitial pneumonitis, including clinically significant radiation pneumonitis will be excluded.~10. Serum HCG test is positive.~11. Other conditions that influence the results and increase the risk of study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- HL-085 (Type: EXPERIMENTAL): HL-085 will be administered as BID with specified dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).